Cargando…

Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients

BACKGROUND: Osteoprotegerin (OPG) is a glycoprotein that plays an important regulatory role in the skeletal, vascular, and immune system. It has been shown that OPG predicts chronic kidney disease (CKD) in diabetic patients. We hypothesized that OPG could be a risk marker of CKD development also in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernardi, Stella, Toffoli, Barbara, Bossi, Fleur, Candido, Riccardo, Stenner, Elisabetta, Carretta, Renzo, Barbone, Fabio, Fabris, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500921/ https://www.ncbi.nlm.nih.gov/pubmed/28683789 http://dx.doi.org/10.1186/s12882-017-0625-3

Ejemplares similares

Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System
por: Toffoli, Barbara, et al.
Publicado: (2016)

A case report of malignant hypertension in a young woman
por: Michelli, Andrea, et al.
Publicado: (2016)

Sex Differences in Proatherogenic Cytokine Levels
por: Bernardi, Stella, et al.
Publicado: (2020)

Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality
por: Kamińska, Joanna, et al.
Publicado: (2021)

TRAIL Modulates the Immune System and Protects against the Development of Diabetes
por: Bossi, Fleur, et al.
Publicado: (2015)

A case report of hyponatremia after surgery for Conn’s adenoma
por: Furlanis, Giulia, et al.
Publicado: (2017)

A prospective study on the efficacy of patient simulation in heart and lung auscultation
por: Bernardi, Stella, et al.
Publicado: (2019)

Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

Preliminary Study on the Effect of a Night Shift on Blood Pressure and Clock Gene Expression
por: Toffoli, Barbara, et al.
Publicado: (2023)

Association of Circulating Osteoprotegerin Level with Blood Pressure Variability in Patients with Chronic Kidney Disease
por: Suh, Sang Heon, et al.
Publicado: (2021)

Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
por: Candido, Riccardo, et al.
Publicado: (2023)

TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake
por: Toffoli, Barbara, et al.
Publicado: (2021)

Children With Short Stature Display Reduced ACE2 Expression in Peripheral Blood Mononuclear Cells
por: Tonon, Federica, et al.
Publicado: (2022)

Circulating Osteoprotegerin Levels Independently Predict All-cause Mortality in Patients with Chronic Kidney Disease: a Meta-analysis
por: Huang, Qing-xiu, et al.
Publicado: (2019)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
por: Chen, Yen-Liang, et al.
Publicado: (2023)

High circulating osteoprotegerin levels are associated with non-zero blood groups
por: Nagy, Elod Erno, et al.
Publicado: (2016)

Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients
por: Nemeth, Zsofia K., et al.
Publicado: (2015)

Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension
por: Condliffe, Robin, et al.
Publicado: (2012)

Therapeutic implications of osteoprotegerin
por: Fili, Sofia, et al.
Publicado: (2009)

The role of osteoprotegerin in arthritis
por: Schett, Georg, et al.
Publicado: (2003)

Osteoprotegerin in Cardiometabolic Disorders
por: Pérez de Ciriza, C., et al.
Publicado: (2015)

Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients
por: Pateinakis, Panagiotis, et al.
Publicado: (2013)

Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5
por: Marques, Gustavo Lenci, et al.
Publicado: (2021)

Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients
por: Okasha, Kamal M., et al.
Publicado: (2022)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

Biology of RANK, RANKL, and osteoprotegerin
por: Boyce, Brendan F, et al.
Publicado: (2007)

A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension
por: Arnold, Nadine D., et al.
Publicado: (2019)

Osteoprotegerin, interleukin and hepatocyte growth factor for prediction of diabetes and hypertension in the third trimester of pregnancy
por: Huang, Su-Jing, et al.
Publicado: (2020)

Serum Osteoprotegerin Is an Independent Marker of Metabolic Complications in Non-DialysisDependent Chronic Kidney Disease Patients
por: Rymarz, Aleksandra, et al.
Publicado: (2021)

Discriminatory Value of Adiponectin to Leptin Ratio for COVID-19 Pneumonia
por: Tonon, Federica, et al.
Publicado: (2022)

Calcium and Osteoprotegerin Levels Predict the Progression of the Abdominal Aortic Calcifications After Kidney Transplantation
por: Meneghini, Maria, et al.
Publicado: (2013)

Role of Osteoprotegerin and Its Gene Polymorphisms in the Occurrence of Left Ventricular Hypertrophy in Essential Hypertensive Patients
por: Shen, Anna, et al.
Publicado: (2014)

Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study
por: Kim, Chang Seong, et al.
Publicado: (2016)

Osteoprotegerin induction in response to microbial infection
por: Takada, Yasunari, et al.
Publicado: (2012)

Expression and Regulation of Osteoprotegerin in Adipose Tissue
por: An, Juan-Ji, et al.
Publicado: (2007)

Renal mineralocorticoid receptor expression is reduced in lipoatrophy
por: Toffoli, Barbara, et al.
Publicado: (2019)

RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)

Osteoprotegerin and Mortality in Type 2 Diabetic Patients
por: Reinhard, Henrik, et al.
Publicado: (2010)

Expression of Osteoprotegerin in Placenta and Its Association with Preeclampsia
por: Shen, Pei, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vdfug1om8a5c4d2iq813rrii8h